Indolent Lymphoma - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 157 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Indolent Lymphoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Indolent Lymphoma - Pipeline Review, H2 2014', provides an overview of the Indolent Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Indolent Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Indolent Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Indolent Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Indolent Lymphoma - Overview 10
Pipeline Products for Indolent Lymphoma - Comparative Analysis 11
Indolent Lymphoma - Therapeutics under Development by Companies 12
Indolent Lymphoma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Unknown Stage Products 16
Indolent Lymphoma - Products under Development by Companies 17
Indolent Lymphoma - Companies Involved in Therapeutics Development 18
Amgen Inc. 18
Astellas Pharma Inc. 19
Bayer AG 20
BioMedics Japan Inc. 21
Biothera, Inc. 22
Boehringer Ingelheim GmbH 23
Celgene Corporation 24
Eagle Pharmaceuticals Inc. 25
Emergent BioSolutions Inc. 26
F. Hoffmann-La Roche Ltd. 27
Gilead Sciences, Inc. 28
Incyte Corporation 29
Infinity Pharmaceuticals, Inc. 30
Kite Pharma, Inc. 31
MedImmune, LLC 32
Merck & Co., Inc. 33
Merck KGaA 34
MorphoSys AG 35
Pharmacyclics, Inc. 36
Sandoz Inc. 37
Indolent Lymphoma - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
bendamustine hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
bendamustine hydrochloride SI - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BI-836826 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
blinatumomab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BM-ca - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
copanlisib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DI-B4 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
duvelisib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GS-9973 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ibrutinib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
idelalisib - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Imprime PGG - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
INCB-050465 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
INCB-40093 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
INCB-40093 + INCB-39110 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
JCAR-015 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
KTE-C19 CAR - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
lenalidomide - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MEDI-551 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
MOR-208 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
obinutuzumab - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
otlertuzumab - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
rituximab biosimilar - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
vorinostat - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Indolent Lymphoma - Recent Pipeline Updates 97
Indolent Lymphoma - Dormant Projects 141
Indolent Lymphoma - Discontinued Products 142
Indolent Lymphoma - Product Development Milestones 143
Featured News & Press Releases 143
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 143
Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 144
Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 145
Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 146
Feb 20, 2013: Mundipharma Reports Publication Of Phase III Data Of Bendamustine Plus Rituximab In Lancet 148
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 149
Dec 03, 2012: Mundipharma Announces Acceptance Of Bendamustine Abstracts At Annual Meeting Of American Society Of Hematology 150
Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH 152
Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies 153
Dec 05, 2010: Calistoga Reports Positive Results From CAL-101 Phase I Trial In Hematologic Malignancies 154
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 157
Disclaimer 157

List of Tables
Number of Products under Development for Indolent Lymphoma, H2 2014 10
Number of Products under Development for Indolent Lymphoma - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Unknown Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Indolent Lymphoma - Pipeline by Amgen Inc., H2 2014 18
Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H2 2014 19
Indolent Lymphoma - Pipeline by Bayer AG, H2 2014 20
Indolent Lymphoma - Pipeline by BioMedics Japan Inc., H2 2014 21
Indolent Lymphoma - Pipeline by Biothera, Inc., H2 2014 22
Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 23
Indolent Lymphoma - Pipeline by Celgene Corporation, H2 2014 24
Indolent Lymphoma - Pipeline by Eagle Pharmaceuticals Inc., H2 2014 25
Indolent Lymphoma - Pipeline by Emergent BioSolutions Inc., H2 2014 26
Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 27
Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2014 28
Indolent Lymphoma - Pipeline by Incyte Corporation, H2 2014 29
Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 30
Indolent Lymphoma - Pipeline by Kite Pharma, Inc., H2 2014 31
Indolent Lymphoma - Pipeline by MedImmune, LLC, H2 2014 32
Indolent Lymphoma - Pipeline by Merck & Co., Inc., H2 2014 33
Indolent Lymphoma - Pipeline by Merck KGaA, H2 2014 34
Indolent Lymphoma - Pipeline by MorphoSys AG, H2 2014 35
Indolent Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2014 36
Indolent Lymphoma - Pipeline by Sandoz Inc., H2 2014 37
Assessment by Monotherapy Products, H2 2014 38
Assessment by Combination Products, H2 2014 39
Number of Products by Stage and Target, H2 2014 41
Number of Products by Stage and Mechanism of Action, H2 2014 43
Number of Products by Stage and Route of Administration, H2 2014 45
Number of Products by Stage and Molecule Type, H2 2014 47
Indolent Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 97
Indolent Lymphoma - Dormant Projects, H2 2014 141
Indolent Lymphoma - Discontinued Products, H2 2014 142